Elvira López-‐OlivaMuñoz, EmiliaMuñozMartínez
40
23.
Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J. y col. 2005. Sources of fatty acids stored in
liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin
Invest 115, 1343-‐1351.
24.
Ginsberg, H.N., Zhang, Y.L., Hernandez-‐Ono, A., 2005. Regulation of plasma triglycerides in
insulinresistanceanddiabetes. ArchMedRes36, 232-‐240.
25.
Greco, D., Kotronen, A.,Westerbacka, J. y col. 2008. Gene expression inhumanNAFLD. Am
J Physiol Gastrointest LiverPhysiol 294, G1281-‐1287.
26.
Hubbard, B., Doege, H., Punreddy, S. y col. 2006. Mice deleted for fatty acid
transport protein 5 have defective bile acid conjugation and are protected from obesity.
Gastroenterology130, 1259-‐1269.
27.
Fabbrini, E., Sullivan, S., Klein, S., 2010. Obesity and nonalcoholic fatty liver
disease: biochemical,metabolic, andclinical implications. Hepatology51, 679-‐689.
28.
Foufelle, F., Ferré, P., 2002. New perspectives in the regulation of hepatic
glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor
sterol regulatoryelement bindingprotein-‐1c.
29.
Munday, M.R., 2002. Regulation of mammalian acetyl-‐CoA carboxylase. Biochem
SocTrans30, 1059-‐1064.
30.
Smith, S.,Witkowski, A., Joshi, A.K., 2003. Structural and functional organizationof
theanimal fattyacidsynthase. ProgLipidRes42, 289-‐317.
31.
Ntambi, J.M., Miyazaki, M., 2004. Regulation of stearoyl-‐CoA desaturases and role
inmetabolism. ProgLipidRes43, 91-‐104.
32.
Yen, C.L., Stone, S.J., Koliwad, S. y col. 2008. Thematic reviewseries: glycerolipids.
DGATenzymes and triacylglycerol biosynthesis. J LipidRes49, 2283-‐2301.
33.
Chen, G., Liang, G., Ou, J. y col. 2004. Central role for liver X receptor in insulin-‐
mediated activation of Srebp-‐1c transcription and stimulation of fatty acid synthesis in
liver. ProcNatl AcadSciUSA101, 11245-‐11250.
34.
Shimano, H., 2001. Sterol regulatory element-‐binding proteins (SREBPs):
transcriptional regulatorsof lipidsyntheticgenes. ProgLipidRes40, 439-‐452.
35.
Dentin, R., Girard, J., Postic, C., 2005. Carbohydrate responsive element binding
protein (ChREBP) and sterol regulatory element binding protein-‐1c (SREBP-‐1c): two key
regulatorsof glucosemetabolismand lipidsynthesis in liver. Biochimie87, 81-‐86.
36.
Tessari, P., Coracina, A., Cosma, A., Tiengo, A., 2009. Hepatic lipid metabolism and non-‐
alcoholic fatty liverdisease. NutrMetabCardiovascDis19, 291-‐302.
37.
Kotronen, A., Seppälä-‐Lindroos, A., Vehkavaara, S. y col. 2009. Liver fat and lipidoxidation
inhumans. Liver Int 29, 1439-‐1446.
38.
Lavoie, J.M., Gauthier, M.S., 2006. Regulation of fat metabolism in the liver: link to non-‐
alcoholichepatic steatosis and impact of physical exercise. CellMol LifeSci 63, 1393-‐1409.
39.
Reddy, J.K., Rao,M.S., 2006. Lipidmetabolismand liver inflammation. II. Fatty liverdisease
and fattyacidoxidation. AmJ Physiol Gastrointest LiverPhysiol 290, G852-‐858.
40.
Leclercq, I.A., Farrell, G.C., Field, J. y col. 2000. CYP2E1 andCYP4Aasmicrosomal catalysts
of lipidperoxides inmurinenonalcoholic steatohepatitis. J Clin Invest 105, 1067-‐1075.
41.
Louet, J.F., Chatelain, F., Decaux, J.F. y col. 2001. Long-‐chain fatty acids regulate liver
carnitine palmitoyltransferase I gene (L-‐CPT I) expression through a peroxisome-‐
proliferator-‐activated receptor alpha (PPARalpha)-‐independent pathway. Biochem J 354,
189-‐197.
42.
Reddy, J.K., Hashimoto, T., 2001. Peroxisomal beta-‐oxidation andperoxisome proliferator-‐
activatedreceptor alpha: anadaptivemetabolic system. AnnuRevNutr21, 193-‐230.
43.
Akiyama, T.E., Nicol, C.J., Fievet, C. y col. 2001. Peroxisomeproliferator-‐activated receptor-‐
alpha regulates lipidhomeostasis, but isnot associatedwithobesity: studieswithcongenic
mouse lines. JBiol Chem276, 39088-‐39093.
44.
Stienstra, R., Mandard, S., Patsouris, D. y col. 2007. Peroxisome proliferator-‐activated
receptor alphaprotects against obesity-‐inducedhepatic inflammation. Endocrinology148,
2753-‐2763.
45.
Harano, Y., Yasui, K., Toyama, T. y col. 2006. Fenofibrate, a peroxisome
proliferator-‐activated receptor alpha agonist, reduces hepatic steatosis and lipid
peroxidation in fatty liver Shionogimicewithhereditary fatty liver. Liver Int 26, 613-‐620.
46.
Adiels, M., Taskinen, M.R., Packard, C. y col. 2006. Overproduction of large VLDL
particles isdrivenby increased liver fat content inman. Diabetologia49, 755-‐765.
